| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Lumasiran sodium | ALN-GO1 | Approved | Alnylam Pharmaceuticals Inc | OXLUMO | United States | Hyperoxaluria, Primary | s:27:"Alnylam Pharmaceuticals Inc"; | 2020-11-19 | Hyperoxaluria; Hyperoxaluria, Primary | Details |
This web search service is supported by Google Inc.
A-Z